128 related articles for article (PubMed ID: 12016390)
1. Comparison of the immunohistochemical expression of EGFR, c-erbB2 and p53 protein between primary and recurrent breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Breast Cancer; 2002; 9(2):111-7. PubMed ID: 12016390
[TBL] [Abstract][Full Text] [Related]
2. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer.
Tsutsui S; Ohno S; Murakami S; Kataoka A; Kinoshita J; Hachitanda Y
Eur J Surg Oncol; 2002 Jun; 28(4):383-7. PubMed ID: 12099646
[TBL] [Abstract][Full Text] [Related]
3. Expression of p53, transforming growth factor alpha, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival.
Reinartz JJ; George E; Lindgren BR; Niehans GA
Hum Pathol; 1994 Oct; 25(10):1075-83. PubMed ID: 7927313
[TBL] [Abstract][Full Text] [Related]
4. p53 protein expression in human breast carcinoma: relationship to expression of epidermal growth factor receptor, c-erbB-2 protein overexpression, and oestrogen receptor.
Poller DN; Hutchings CE; Galea M; Bell JA; Nicholson RA; Elston CW; Blamey RW; Ellis IO
Br J Cancer; 1992 Sep; 66(3):583-8. PubMed ID: 1355662
[TBL] [Abstract][Full Text] [Related]
5. Age-associated biomarker profiles of human breast cancer.
Eppenberger-Castori S; Moore DH; Thor AD; Edgerton SM; Kueng W; Eppenberger U; Benz CC
Int J Biochem Cell Biol; 2002 Nov; 34(11):1318-30. PubMed ID: 12200028
[TBL] [Abstract][Full Text] [Related]
6. c-erbB-2 protein overexpression and p53 immunoreaction in primary and recurrent breast cancer tissues.
Shimizu C; Fukutomi T; Tsuda H; Akashi-Tanaka S; Watanabe T; Nanasawa T; Sugihara K
J Surg Oncol; 2000 Jan; 73(1):17-20. PubMed ID: 10649273
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of p53, c-erbB-2 and epidermal growth factor receptor on head and neck carcinoma.
Parise Junior O; Carvalho LV; Miguel RE; Kowalski LP
Sao Paulo Med J; 2004 Nov; 122(6):264-8. PubMed ID: 15692721
[TBL] [Abstract][Full Text] [Related]
8. Expression of c-erbB3 protein in primary breast carcinomas.
Naidu R; Yadav M; Nair S; Kutty MK
Br J Cancer; 1998 Nov; 78(10):1385-90. PubMed ID: 9823984
[TBL] [Abstract][Full Text] [Related]
9. Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.
Toi M; Tominaga T; Osaki A; Toge T
Breast Cancer Res Treat; 1994 Jan; 29(1):51-8. PubMed ID: 7912567
[TBL] [Abstract][Full Text] [Related]
10. C-erbB-2 expression is a better predictor for survival than galectin-3 or p53 in early-stage breast cancer.
Logullo AF; Lopes AB; Nonogaki S; Soares FA; Netto MM; Nishimoto IN; Brentani MM
Oncol Rep; 2007 Jul; 18(1):121-6. PubMed ID: 17549356
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of p53 and c-erbB2 proteins in breast cancer in Egypt.
el-A Helal T; Khalifa A; Kamel AS
Anticancer Res; 2000; 20(3B):2145-50. PubMed ID: 10928168
[TBL] [Abstract][Full Text] [Related]
12. Multivariate analysis of DNA ploidy, p53, c-erbB-2 proteins, EGFR, and steroid hormone receptors for prediction of poor short term prognosis in breast cancer.
Eissa S; Khalifa A; el-Gharib A; Salah N; Mohamed MK
Anticancer Res; 1997; 17(2B):1417-23. PubMed ID: 9137508
[TBL] [Abstract][Full Text] [Related]
13. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
Göhring UJ; Scharl A; Ahr A
Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
[TBL] [Abstract][Full Text] [Related]
14. Clinical response to primary letrozole therapy in elderly patients with early breast cancer: possible role for p53 as a biomarker.
Garimella V; Hussain T; Agarwal V; Radhakrishna S; Fox JN; Kneeshaw PJ; Long ED; Mahapatra TK; McManus PL; Lind MJ; Drew PJ; Cawkwell L
Int J Surg; 2014; 12(8):821-6. PubMed ID: 25010604
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor, c-erbB-2 and p53 overexpressions in epithelial hyperplastic lesions of the larynx.
Gale N; Zidar N; Kambic V; Poljak M; Cör A
Acta Otolaryngol Suppl; 1997; 527():105-10. PubMed ID: 9197495
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.
Järvinen TA; Holli K; Kuukasjärvi T; Isola JJ
Br J Cancer; 1998 Jun; 77(12):2267-73. PubMed ID: 9649144
[TBL] [Abstract][Full Text] [Related]
17. Angiogenesis, p53, and c-erbB-2 immunoreactivity and clinicopathological features in male breast cancer.
Shpitz B; Bomstein Y; Sternberg A; Klein E; Liverant S; Groisman G; Bernheim J
J Surg Oncol; 2000 Dec; 75(4):252-7. PubMed ID: 11135266
[TBL] [Abstract][Full Text] [Related]
18. A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma.
Gasparini G; Boracchi P; Bevilacqua P; Mezzetti M; Pozza F; Weidner N
Breast Cancer Res Treat; 1994 Jan; 29(1):59-71. PubMed ID: 7912568
[TBL] [Abstract][Full Text] [Related]
19. Reassessing tumor markers in local recurrences of breast cancer: a new insight.
Pedrini JL; Pedrini M; Savaris RF; Machado L; Grudzinski M; Zettler CG
Med Sci Monit; 2004 Dec; 10(12):BR462-7. PubMed ID: 15567977
[TBL] [Abstract][Full Text] [Related]
20. The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer.
Korkolopoulou P; Christodoulou P; Kapralos P; Exarchakos M; Bisbiroula A; Hadjiyannakis M; Georgountzos C; Thomas-Tsagli E
Pathol Res Pract; 1997; 193(11-12):767-75. PubMed ID: 9521509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
